Estimating Trunk and Neck Stabilization for Avoiding Head Impact during Real-World Falls in Older Adults

2020 ◽  
Author(s):  
Calvin Kuo ◽  
Nataliya Shishov ◽  
Karam Elabd ◽  
Vicki Komisar ◽  
Helen Chong ◽  
...  
Keyword(s):  
Older Adults ◽  
Real World ◽  
Head Impact ◽  
Falls In Older Adults ◽  
Neck Stabilization

scholarly journals CAPTURING REAL-WORLD LOSSES OF BALANCE AND RECOVERY RESPONSES IN OLDER ADULTS AT RISK FOR FALLS

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S9-S9
Author(s):  
Neil Alexander ◽  
Shirley Handelzalts-Pereg ◽  
Linda Nyquist ◽  
Debbie Strasburg ◽  
Nicholas Mastruserio ◽  
...  
Keyword(s):  
Older Adults ◽  
At Risk ◽  
Real World ◽  
Trunk Motion ◽  
Falls In Older Adults ◽  
Measurement Units ◽  
Near Falls ◽  
Voice Recorder ◽  
The Voice ◽  
Full Body

Abstract Losses of balance (LOBs) such as trips can lead to falls in older adults; what actually happens during real-world LOBs is unclear. With 4 wearable inertial measurement units (IMUs), we recorded feet, trunk and wrist movements over 2 weeks. Using a wrist voice recorder to report the LOBs, we applied our IMU processing algorithms and reconstructed the full body LOB and recovery motions. We recruited 7 at-risk older adults (M=76 yrs) who reported 114 LOBs of which we reconstructed over 90%. Using a rating system, 52% of the LOBs involved a significant trip, stumble, recovery step, and/or large trunk motion. 25% involved double or stutter steps and smaller trunk motions. The other 23% had less striking associated motions. These data suggest that most, but not all, self-reported real world LOBs involve substantial postural destabilization and near falls. Analyses of the voice-recorded context under which the LOBs occurred are ongoing.

Clinical Risk Factors for Head Impact During Falls in Older Adults

2017 ◽  
Vol 32 (3) ◽  
pp. 168-177 ◽  
Author(s):  
Yijian Yang ◽  
Dawn C. Mackey ◽  
Teresa Liu-Ambrose ◽  
Pet-Ming Leung ◽  
Fabio Feldman ◽  
...  
Keyword(s):  
Risk Factors ◽  
Older Adults ◽  
Head Impact ◽  
Clinical Risk Factors ◽  
Clinical Risk ◽  
Falls In Older Adults

scholarly journals Prevalence of and factors associated with head impact during falls in older adults in long-term care

2013 ◽  
Vol 185 (17) ◽  
pp. E803-E810 ◽  
Author(s):  
R. Schonnop ◽  
Y. Yang ◽  
F. Feldman ◽  
E. Robinson ◽  
M. Loughin ◽  
...  
Keyword(s):  
Older Adults ◽  
Long Term Care ◽  
Head Impact ◽  
Term Care ◽  
Factors Associated ◽  
Falls In Older Adults

Stepping impairment and falls in older adults: A systematic review and meta-analysis of volitional and reactive step tests

2020 ◽  
pp. 101238
Author(s):  
Yoshiro Okubo ◽  
Daniel Schoene ◽  
Maria JD Caetano ◽  
Erika M Pliner ◽  
Yosuke Osuka ◽  
...  
Keyword(s):  
Systematic Review ◽  
Older Adults ◽  
Meta Analysis ◽  
Falls In Older Adults

scholarly journals 1012. Efficacy, safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected virologically-suppressed older adults in a real-world setting

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S534-S535
Author(s):  
Charlotte-Paige M Rolle ◽  
Vu Nguyen ◽  
Kiran Patel ◽  
Dan Cruz ◽  
Federico Hinestrosa ◽  
...  
Keyword(s):  
Older Adults ◽  
Drug Interactions ◽  
Real World ◽  
Research Study ◽  
Panel Member ◽  
Median Number ◽  
Research Support ◽  
Review Panel ◽  
Study Investigator ◽  
Hiv 1

Abstract Background Approximately 50% of people living with HIV (PLWH) in the United States are ≥50 years old. Efforts are ongoing to identify antiretrovirals associated with fewer drug-drug interactions (DDIs) and long-term side effects in this group. Clinical trials of B/F/TAF demonstrated favorable efficacy and safety in older adults, however, data from real-word settings are needed to validate these results. Methods This retrospective analysis evaluated records from PLWH aged ≥ 50 years at the Orlando Immunology Center who were switched to B/F/TAF between 2/7/2018 and 5/31/2019. Eligible patients had baseline HIV-1 RNA< 50 copies/mL and were followed for 48 weeks post-switch. The primary endpoint was maintenance of HIV-1 RNA< 50 copies/mL at week 48. The impact of switching to B/F/TAF on DDIs, adverse events (AEs) and safety parameters were analyzed throughout the study. Results 306 patients met inclusion criteria. 62 (20%) were female, 126 (41%) were non-white, median age was 58 years (range [r] 50-81), median duration of HIV infection was 19.5 years (r 2-40), median number of chronic co-morbid conditions was 5 (r 0-20), and median number of baseline concomitant medications was 4 (r 0-23). 159 (52%) patients were switched from regimens containing ritonavir or cobicistat. The most commonly documented reason for switch was simplification (Table 1). At Week 48, 287 (94%) patients maintained an HIV-1 RNA< 50 copies/ml and 19 (6%) had an HIV-1 RNA between 50-200 copies/mL (Figure 1). 1 patient discontinued due to lack of efficacy. A total of 123 potential DDIs were identified in 104 (34%) patients taking a boosting agent or rilpivirine at baseline (Table 2). At Week 48, there was a significant median decline in total cholesterol (15.5 mg/dL, 95% confidence interval [CI]: 9.5; 21.5), LDL cholesterol (9.5 mg/dL, 95% CI: 4; 15.5) and triglycerides (20 mg/dL, 95% CI: 9.5; 32.5), and median weight increased by 2.5 pounds (95% CI: 1.5; 3.5). Treatment-related AEs occurred in 33 (11%) patients (all Grade 1-2) and led to 7 (2%) discontinuations. Table 1-Baseline demographic and clinical characteristics Table 2-Avoidance of Drug-Drug Interactions (DDIs) following switch to B/F/TAF Figure 1-Subgroup analysis of virologic outcomes at Week 48 Conclusion In this real-world cohort, switching to B/F/TAF was associated with maintenance of virologic control, improvement in lipid parameters, and avoidance of DDIs in a large proportion of patients. These data support use of B/F/TAF as a treatment option in older PLWH. Disclosures Charlotte-Paige M. Rolle, MD MPH, Gilead Sciences (Grant/Research Support, Scientific Research Study Investigator, Speaker’s Bureau)Janssen Infectious Disease (Grant/Research Support)ViiV Healthcare (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau) Kiran Patel, PharmD, Gilead Sciences (Employee) Federico Hinestrosa, MD, AbbVie (Speaker’s Bureau)Gilead Sciences (Speaker’s Bureau)Merck (Speaker’s Bureau)Theratechnologies (Speaker’s Bureau) Edwin DeJesus, MD, Gilead Sciences (Advisor or Review Panel member)

Sign in / Sign up

Export Citation Format

Share Document